ACTIVATE: The effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 2545-2558

  Watz, Henrik ^a   Troosters, Thierry ^b   Beeh, Kai M ^c   Garcia Aymerich, Judith ^d,e,f   Paggiaro, Pierluigi ^g   Molins, Eduard ^h   Notari, Massimo ⁱ   Zapata, Antonio ^j   Jarreta, Diana ^h   Garcia Gil, Esther ^h  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Institut fur Atemwegsforschung INSAF   (Germany)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g UNIVERSITY OF PISA   (Italy)

^h ASTRAZENECA   (United Kingdom)

ⁱ A Menarini Farmaceutica Internazionale SRL   (Italy)

^j Laboratorios Menarini SA   (Spain)

more..

Author keywords

Aclidinium; COPD; Exercise capacity; Formoterol; Hyperinflation; Physical activity

Indexed keywords

ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; PLACEBO; ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG WITHDRAWAL; DRY POWDER INHALER; EXERCISE; FEMALE; FUNCTIONAL RESIDUAL CAPACITY; HEADACHE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; RESIDUAL VOLUME; RHINOPHARYNGITIS; AGED; CANADA; CLINICAL TRIAL; CONVALESCENCE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; EUROPE; EXERCISE TOLERANCE; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CANADA; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EUROPE; EXERCISE; EXERCISE TOLERANCE; FEMALE; FORMOTEROL FUMARATE; FUNCTIONAL RESIDUAL CAPACITY; HUMANS; INSPIRATORY CAPACITY; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; TROPANES;

EID: 85028616482     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S143488     Document Type: Article

References (38)

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214.
2. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521–1537.
3. Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–1122.
4. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262–272.
5. van Remoortel H, Hornikx M, Demeyer H, et al. Daily physical activity in subjects with newly diagnosed COPD. Thorax. 2013;68(10):962–963.
6. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106(4):522–530.
7. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46(5):1281–1289.
8. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(3):295–306.
9. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342.
10. Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.
11. Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802.
12. Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22(1):101–111.
13. Troosters T, Bourbeau J, Maltais F, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016;6(4):e010106.
14. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–513.
15. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178.
16. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105(4):580–587.
17. O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030–1036.
18. Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Med. 2014;14(1):209.
19. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease–a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med. 2014;14:158.
20. Watz H, Mailänder C, Baier M, Kirsten A. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Med. 2016;16(1):95.
21. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
22. Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72(5):415–423.
23. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522.
24. Coates AL, Peslin R, Rodenstein D, Stocks J. Measurement of lung volumes by plethysmography. Eur Respir J. 1997;10(6):1415–1427.
25. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
26. Rabinovich RA, Louvaris Z, Raste Y, et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J. 2013;42(5):1205–1215.
27. Gimeno-Santos E, Raste Y, Demeyer H; PROactive consortium, et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2015;46(4):988–1000.
28. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108(4):584–592.
29. O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348.
30. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
31. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47(2):429–460.
32. Moy ML, Collins RJ, Martinez CH, et al. An internet-mediated pedometer-based program improves health-related quality-of-life domains and daily step counts in COPD: a randomized controlled trial. Chest. 2015;148(1):128–137.
33. Mendoza L, Horta P, Espinoza J, et al. Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur Respir J. 2015;45(2):347–354.
34. Bourbeau J, Lavoie KL, Sedeno M, et al. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation. BMJ Open. 2016;6(4):e010109.
35. Demeyer H, Burtin C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One. 2016;11(4):e0154587.
36. Santus P, Radovanovic D, Balzano G, et al. Improvements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneity. Respiration. 2016;92(5):295–307.
37. Santus P, Radovanovic D, Di Marco F, Raccanelli R, Valenti V, Centanni S. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
38. Moy ML, Martinez CH, Kadri R, et al. Long-term effects of an internet-mediated pedometer-based walking program for chronic obstructive pulmonary disease: randomized controlled trial. J Med Internet Res. 2016;18(8):e215.